Faculty Opinions recommendation of Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase III Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors

Arthritis & Rheumatology ◽

10.1002/art.40753 ◽

2019 ◽

Vol 71 (4) ◽

pp. 599-611 ◽

Cited By ~ 54

Author(s):

Atul Deodhar ◽

Denis Poddubnyy ◽

Cesar Pacheco‐Tena ◽

Carlo Salvarani ◽

Eric Lespessailles ◽

...

Keyword(s):

Tumor Necrosis ◽

Axial Spondyloarthritis ◽

Controlled Trial ◽

Phase Iii ◽

Inadequate Response ◽

Tumor Necrosis Factor Inhibitors ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

10.1002/art.22025 ◽

2006 ◽

Vol 54 (9) ◽

pp. 2793-2806 ◽

Cited By ~ 1041

Author(s):

Stanley B. Cohen ◽

Paul Emery ◽

Maria W. Greenwald ◽

Maxime Dougados ◽

Richard A. Furie ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis ◽

Phase Iii ◽

Primary Efficacy ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Factor Therapy ◽

Faculty Opinions recommendation of Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718325315.793492809 ◽

2014 ◽

Author(s):

Ronald van Vollenhoven

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis ◽

Phase Iii ◽

Primary Efficacy ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Factor Therapy ◽

Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials

Clinical Rheumatology ◽

10.1007/s10067-019-04595-1 ◽

2019 ◽

Vol 38 (10) ◽

pp. 2765-2776 ◽

Cited By ~ 6

Author(s):

Yanrong Huang ◽

Yong Fan ◽

Yang Liu ◽

Wenhui Xie ◽

Zhuoli Zhang

Keyword(s):

Tumor Necrosis ◽

Active Rheumatoid Arthritis ◽

Meta Analysis ◽

Phase Iii ◽

Controlled Trials ◽

Inadequate Response ◽

Tumor Necrosis Factor Inhibitors ◽

Efficacy And Safety ◽

Randomized Controlled ◽

Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

10.1002/art.27348 ◽

2010 ◽

Vol 62 (4) ◽

pp. 917-928 ◽

Cited By ~ 76

Author(s):

Joel Kremer ◽

Christopher Ritchlin ◽

Alan Mendelsohn ◽

Daniel Baker ◽

Lilianne Kim ◽

...

Keyword(s):

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Active Rheumatoid Arthritis ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Α ◽

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial

10.1002/art.33353 ◽

2012 ◽

Vol 64 (2) ◽

pp. 360-370 ◽

Cited By ~ 41

Author(s):

P. P. Tak ◽

P. J. Mease ◽

M. C. Genovese ◽

J. Kremer ◽

B. Haraoui ◽

...

Keyword(s):

Tumor Necrosis ◽

Tumor Necrosis Factor Inhibitor ◽

Phase Iii ◽

Inadequate Response ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Parallel Group ◽

Factor Inhibitor ◽

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumor necrosis factor inhibitors: OPAL Beyond, a randomized, double blind, placebo-controlled, phase 3 trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2017.04.451 ◽

2017 ◽

Vol 76 (6) ◽

pp. AB114

Keyword(s):

Tumor Necrosis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Inadequate Response ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo ◽

Erratum: Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

10.1002/art.27747 ◽

2010 ◽

Vol 62 (10) ◽

pp. 3130-3130 ◽

Cited By ~ 2

Author(s):

Joel Kremer ◽

Christopher Ritchlin ◽

Alan Mendelsohn ◽

Daniel Baker ◽

Lilianne Kim ◽

...

Keyword(s):

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Active Rheumatoid Arthritis ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Α ◽

OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial

10.1136/annrheumdis-2017-eular.2443 ◽

2017 ◽

Cited By ~ 3

Author(s):

DD Gladman ◽

WFC Rigby ◽

VF Azevedo ◽

F Behrens ◽

R Blanco ◽

...

Keyword(s):

Tumour Necrosis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Inadequate Response ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo ◽

Ustekinumab in active psoriatic arthritis including patients previously treated with anti–tumor necrosis factor agents: Week 24 results from PSUMMIT 2, a phase III, multicenter, double-blind, placebo-controlled study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2012.12.895 ◽

2013 ◽

Vol 68 (4) ◽

pp. AB217

Keyword(s):

Psoriatic Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Phase Iii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Previously Treated ◽